607 related articles for article (PubMed ID: 20816021)
41. The role of incretin hormones and glucagon in patients with liver disease.
Junker AE
Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
[TBL] [Abstract][Full Text] [Related]
42. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.
D'Alessio DA; Kahn SE; Leusner CR; Ensinck JW
J Clin Invest; 1994 May; 93(5):2263-6. PubMed ID: 8182159
[TBL] [Abstract][Full Text] [Related]
43. Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion.
Lund A; Bagger JI; Christensen M; Grøndahl M; van Hall G; Holst JJ; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2016 Nov; 101(11):4377-4384. PubMed ID: 27533305
[TBL] [Abstract][Full Text] [Related]
44. Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice.
Irwin N; McClean PL; Harriott P; Flatt PR
Exp Gerontol; 2007 Apr; 42(4):296-300. PubMed ID: 17184947
[TBL] [Abstract][Full Text] [Related]
45. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.
Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Cahen DL; van Raalte DH
Diabetes Obes Metab; 2016 Mar; 18(3):224-35. PubMed ID: 26500045
[TBL] [Abstract][Full Text] [Related]
46. Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects.
Meier JJ; Deacon CF; Schmidt WE; Holst JJ; Nauck MA
Diabetologia; 2007 Apr; 50(4):806-13. PubMed ID: 17334652
[TBL] [Abstract][Full Text] [Related]
47. Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs.
Oda H; Mori A; Lee P; Saeki K; Ishioka K; Arai T; Sako T
Res Vet Sci; 2013 Oct; 95(2):381-8. PubMed ID: 23632200
[TBL] [Abstract][Full Text] [Related]
48. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia.
Junker AE; Gluud L; Holst JJ; Knop FK; Vilsbøll T
J Intern Med; 2016 May; 279(5):485-93. PubMed ID: 26728692
[TBL] [Abstract][Full Text] [Related]
49. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.
Ahrén B; Larsson H; Holst JJ
J Clin Endocrinol Metab; 1997 Feb; 82(2):473-8. PubMed ID: 9024239
[TBL] [Abstract][Full Text] [Related]
50. Poly-GLP-1, a novel long-lasting glucagon-like peptide-1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta-cell proliferation.
Ma X; Hui H; Liu Z; He G; Hu J; Meng J; Guan L; Luo X
Diabetes Obes Metab; 2009 Oct; 11(10):953-65. PubMed ID: 19531053
[TBL] [Abstract][Full Text] [Related]
51. GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes.
Halden TA; Egeland EJ; Åsberg A; Hartmann A; Midtvedt K; Khiabani HZ; Holst JJ; Knop FK; Hornum M; Feldt-Rasmussen B; Jenssen T
Diabetes Care; 2016 Apr; 39(4):617-24. PubMed ID: 26908914
[TBL] [Abstract][Full Text] [Related]
52. Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes.
Meneilly GS; McIntosh CH; Pederson RA; Habener JF; Gingerich R; Egan JM; Elahi D
J Gerontol A Biol Sci Med Sci; 2001 Nov; 56(11):M681-5. PubMed ID: 11682575
[TBL] [Abstract][Full Text] [Related]
53. Effect of glucagon-like peptide-1 on beta- and alpha-cell function in isolated islet and whole pancreas transplant recipients.
Rickels MR; Mueller R; Markmann JF; Naji A
J Clin Endocrinol Metab; 2009 Jan; 94(1):181-9. PubMed ID: 18957498
[TBL] [Abstract][Full Text] [Related]
54. Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes.
Borg MJ; Bound M; Grivell J; Sun Z; Jones KL; Horowitz M; Rayner CK; Wu T
Diabetes Obes Metab; 2019 Mar; 21(3):640-647. PubMed ID: 30370686
[TBL] [Abstract][Full Text] [Related]
55. Relationship between metabolic syndrome and meal-induced glucagon like peptide-1 response in type 1 diabetic patients1-1.
Blaslov K; Bulum T; Zibar K; Duvnjak L
J Diabetes; 2015 May; 7(3):340-6. PubMed ID: 25042812
[TBL] [Abstract][Full Text] [Related]
56. Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease.
Junker AE; Gluud LL; van Hall G; Holst JJ; Knop FK; Vilsbøll T
J Hepatol; 2016 Apr; 64(4):908-15. PubMed ID: 26626496
[TBL] [Abstract][Full Text] [Related]
57. Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretion.
Abdul-Ghani M; DeFronzo RA
J Clin Endocrinol Metab; 2007 May; 92(5):1778-84. PubMed ID: 17327375
[TBL] [Abstract][Full Text] [Related]
58. GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes.
Tomas E; Stanojevic V; Habener JF
Horm Metab Res; 2010 Aug; 42(9):657-62. PubMed ID: 20645222
[TBL] [Abstract][Full Text] [Related]
59. Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: a potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?
Daousi C; Pinkney JH; Cleator J; Wilding JP; Ranganath LR
Regul Pept; 2013 May; 183():54-61. PubMed ID: 23499806
[TBL] [Abstract][Full Text] [Related]
60. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.
Scheen AJ; Castillo MJ; Lefèbvre PJ
Diabetes Metab; 1996 Dec; 22(6):397-406. PubMed ID: 8985647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
